Anuh Pharma Downgraded to 'Hold' by MarketsMOJO, But Shows Positive Results and Fair Valuation

Anuh Pharma, a smallcap pharmaceutical company, has recently been downgraded to a 'Hold' by MarketsMOJO on May 6, 2024. This decision was based on the company's low Debt to Equity ratio, which is currently at 0 times.
However, the company has shown positive results in the last three consecutive quarters, with a growth in Net Profit of 38.18%. In fact, in December 2023, Anuh Pharma declared very positive results. The company's PBT LESS OI(Q) was the highest at Rs 21.65 crore, while its PAT(Q) and NET SALES(Q) were also at their highest at Rs 19.11 crore and Rs 172.10 crore, respectively.

Technically, the stock is in a mildly bullish range, with its MACD and KST technical factors also showing a bullish trend. Anuh Pharma's ROE of 21.2 indicates a fair valuation, with a price to book value of 4.6. The stock is currently trading at a fair value compared to its average historical valuations.

In the past year, Anuh Pharma has generated a return of 169.02%, while its profits have risen by 53%. This gives the company a PEG ratio of 0.4, indicating a market-beating performance in both the long term and near term.

Despite its smallcap size, domestic mutual funds hold only 0% of the company. This could signify that they are not comfortable with the current price or the business, as they have the capability to conduct in-depth on-the-ground research on companies.

Overall, while Anuh Pharma may have been downgraded to a 'Hold', its positive results and fair valuation make it a company worth keeping an eye on in the pharmaceutical industry.